PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Sherman, Kenneth
TI  - ALLY 2
DP  - 2015 Sep 07
TA  - MD Conference Express
PG  - 9--10
VI  - 15
IP  - 14
4099  - http://mdc.sagepub.com/content/15/14/9.short
4100  - http://mdc.sagepub.com/content/15/14/9.full
AB  - Results of the ALLY 2 trial involving more than 200 patients co-infected with HIV/HCV shows the efficacy and safety of the combined 12-week use of daclatasvir and sofosbuvir, with sustained virologic response for 12 weeks of 97% after a 12-week treatment. The benefit for HCV infection does not compromise the ongoing antiretroviral therapy.